Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.50 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.50 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7428120 | 0.90 | HDAC1 (0.56) | SYKKMT2ATDP1MEN1SLC6A2 | |
| SCHEMBL14485285 | 0.89 | SYK (0.62) | SYKKMT2ATDP1MEN1LMNA | |
| SCHEMBL23181123 | 0.88 | RAB9A (0.54) | SYKKMT2ATDP1MEN1SLC6A2 | |
| SCHEMBL7289218 | 0.86 | HDAC1 (0.56) | SYKKMT2ATDP1MEN1LMNA | |
| SCHEMBL2572854 | 0.86 | HDAC1 (0.58) | SYKKMT2ATDP1MEN1SLC6A2 | |
| SCHEMBL3838871 | 0.85 | CA12 (0.63) | SYKKMT2AMEN1LMNAHDAC1 | |
| SCHEMBL25054127 | 0.84 | SYK (0.55) | SYKKMT2ATDP1MEN1HDAC1 | |
| SCHEMBL4457324 | 0.84 | KMT2A (0.51) | SYKKMT2AMEN1HDAC1NTSR1 | |
| SCHEMBL3905352 | 0.84 | HTT (0.59) | KMT2AMEN1LMNAHDAC1MAPT | |
| SCHEMBL3940116 | 0.84 | NAMPT (0.60) | SYKKMT2ATDP1MEN1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133892-A1 | Chimeric Compounds and Methods of Managing Neurological Disorders or Conditions | UNIV EMORY (US) | 2022-05-05 | — | — | US | disclosed |
| US-20050221318-A1 | Building block forming a c-c bond upon reaction | NUEVOLUTION A/S (DK) | 2005-10-06 | — | — | US | disclosed |
| WO-2005030709-A1 | NOVEL SULFONE AMIDE DERIVATIVES CAPABLE OF INHIBITING BACE | LG LIFE SCIENCES LTD. (KR) | 2005-04-07 | — | — | WO | disclosed |
| EP-1490384-A2 | A BUILDING BLOCK FORMING A C-C BOND UPON REACTION | Nuevolution A/S (DK) | 2004-12-29 | — | — | EP | disclosed |
| EP-1487848-A2 | A BUILDING BLOCK FORMING A C=C DOUBLE BOND UPON REACTION | Nuevolution A/S (DK) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078445-A2 | A BUILDING BLOCK FORMING A C=C DOUBLE BOND UPON REACTION | NUEVOLUTION A/S (DK) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003078050-A2 | A BUILDING BLOCK FORMING A C-C BOND UPON REACTION | NUEVOLUTION A/S (DK) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133892-A1 | Chimeric Compounds and Methods of Managing Neurological Disorders or Conditions | MAOA, HNMT, HDAC6 | SYK 4463/4885KMT2A 19/4885TDP1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.